Latest studies
- Active not recruitingPHASE3
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
This study looks at the long-term safety and effectiveness of a medicine called ocrelizumab for people with Multiple Sclerosis (MS). It's for people already taking part in other ocrelizumab studies, to see how the treatment works over a longer time.
Multiple SclerosisTunisia - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
This study is looking at a new combination of treatments, Inavolisib and Phesgo, for HER2-positive breast cancer that has spread. We want to see if this new combination works better and is safe compared to Phesgo alone after initial treatment.
Metastatic Breast CancerTunisia - Recruiting
eUltra 10k - Biofreedom Ultra
This study is gathering real-world information on the BioFreedom Ultra stent, a small tube used to keep blood vessels open. It's for people aged 18 and over who have this stent, helping researchers understand how it works in everyday medical care.
Post Market Clinical Follow up (PMCF)Tunisia - RecruitingPHASE3
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
This study looks at a new medicine called orforglipron for people with heart disease or kidney disease. We want to see if it can improve their heart health over about five years. Half the people will get the new medicine, and half will get a dummy medicine (placebo).
Atherosclerosis Cardiovascular DiseaseChronic Kidney DiseaseTunisia - Active not recruitingPHASE3
A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
This study looks at a new injection called efgartigimod for adults with primary immune thrombocytopenia (ITP). It aims to see how safe and effective it is. If you've been in a previous study for this treatment, you might be able to continue.
Primary Immune ThrombocytopeniaTunisia - Active not recruitingPHASE3
A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome
This study is looking into a new treatment called efgartigimod for people with Primary Sjögren's Syndrome. It aims to see how well it works and if it's safe. Participants will either receive the new medicine or a dummy treatment, and the study will last about two years.
Primary Sjogrens DiseaseTunisia - Active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
This study is looking at a new treatment called Ocrelizumab for primary progressive multiple sclerosis (PPMS). It compares Ocrelizumab to a dummy drug (placebo) to see how safe and effective it is for adults, including those who have had PPMS for a while.
Multiple Sclerosis, Primary ProgressiveTunisia - Active not recruitingPHASE2, PHASE3
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
This study looks at a new medicine called guselkumab for adults with moderately to severely active Crohn's disease. Researchers want to see how well it works and if it's safe compared to other treatments or a dummy medicine.
Crohn's DiseaseTunisia - Recruiting
Post Marketing Clinical Follow Up Study to Evaluate Efficacy and Safety of the Occlutech PDA Occluder in Patients With Patent Ductus Arteriosus Defects
This study looks at how well and how safely a special device, called the Occlutech® PDA Occluder, works to close a heart condition called Patent Ductus Arteriosus (PDA) in patients. It follows people over a few years after the device is put in.
Patent Ductus ArteriosusTunisia - Active not recruitingPHASE3
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
This study is testing a new medicine, barzolvolimab, for people with chronic spontaneous urticaria (CSU), also known as chronic hives. It aims to see if the medicine is safe and helps reduce hives better than a dummy medicine (placebo) for those whose current treatments aren't enough.
Chronic Spontaneous UrticariaTunisia - RecruitingPHASE3
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
This study looks at the long-term safety of a medicine called luspatercept for people with certain blood disorders. It's for those already taking part in a luspatercept study to see if continuing the treatment is safe over a longer period.
Myelodysplastic Syndromes (MDS)Beta-thalassemiaMyeloproliferative Neoplasm(MPN)-Associated MyelofibrosisTunisia - RecruitingPHASE1, PHASE2
Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine)
This study is testing a new medicine, ABO-101, for people with a rare kidney condition called Primary Hyperoxaluria Type 1 (PH1). It looks at how safe the medicine is, how well the body handles it, and if it could help. It involves both adults and children.
Primary Hyperoxaluria Type 1 (PH1)Tunisia - Recruiting
A Long-Term Observational Study of Patients With Fucosidosis
This study wants to learn more about fucosidosis, a rare condition, by collecting information from people who have it. It helps doctors understand the condition better for future treatments. No new medicines or treatments are given.
FucosidosisTunisia - Active not recruitingPHASE4
A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis
This study looks at how a medicine called emicizumab affects the overall health, activity levels, and joints of people with moderate or severe haemophilia A. It's for those already receiving another treatment and planning to switch to emicizumab.
Severe Hemophilia AModerate Hemophilia ATunisia